title: Analyze Association of BRCA2 Arg372His Polymorphism With Ovarian Cancer Risk.
abstract: OBJECTIVE
  Studies investigating the association between BRCA2 Arg372His polymorphism and ovarian cancer risks have yielded conflicting results.
  
  
  METHODS
  We carried out a meta-analysis of 8488 ovarian cancer cases and 14,510 controls from 7 case-control studies in 5 articles published. The association between BRCA2 Arg372His polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) appropriately derived from fixed effects models.
  
  
  RESULTS
  There were no significant associations between BRCA2 Arg372His polymorphisms and ovarian cancer risk in overall comparisons in all genetic models (HH vs NN: OR, 1.06; 95% confidence interval [95% CI], 0.96-1.18; P = 0.25; NH vs NN: OR, 1.02; 95% CI, 0.96-1.07; P = 0.6; NH + HH vs NN: OR, 1.01; 95% CI, 0.98-1.04; P = 0.42; HH vs NN + NH: OR, 1.06; 95% CI, 0.95-1.17; P = 0.29).
  
  
  CONCLUSIONS
  This meta-analysis indicates that the BRCA2 Arg372His polymorphism is not associated with ovarian cancer risk for whites. Asian and African populations should be further studied.
authors.affiliation: *Shandong Provincial Key Laboratory of Microbiological Engineering, Qilu University of Technology; and †Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong, P.R. China.
authors.forename: Cunfang
authors.initials: C
authors.lastname: Wang
authors.forename: Cunzhong
authors.initials: C
authors.lastname: Yuan
mesh_terms: D024682:BRCA2 Protein / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D024682:BRCA2 Protein; C551750:BRCA2 protein, human